Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis

This review (81 studies; n=11,151) found estimated 5-year disease-free (64% v 25%) and overall survival (68% v 34%) were higher in patients without than in those with measurable residual disease, supporting use as an endpoint in AML studies, to allow for accelerated evaluation.

JAMA Oncology